The American Medical Association, Chicago, filed a federal lawsuit on Dec. 2, 1999, charging Donna E. Shalala, secretary of the U.S. Department of Health and Human Services, with failure to exert her authority and correct errors in the system used by Medicare to pay physicians for care provided to the nation's elderly.
The American Medical Association, Chicago, filed a federal lawsuit on Dec. 2, 1999, charging Donna E. Shalala, secretary of the U.S. Department of Health and Human Services, with failure to exert her authority and correct errors in the system used by Medicare to pay physicians for care provided to the nation's elderly.
The AMA's main concern is how the sustainable growth rate, a critical component in the methodology used by the Health Care Financing Administration to adjust the annual update of payments for physician services under Medicare, was calculated in 1998 and 1999.
The AMA maintains that, by continuing to use projections instead of actual values, HCFA underestimated growth in Medicare spending. HCFA's failure to correct the errors, the AMA contends, resulted in an unlawful fiscal burden for physicians estimated at $3 billion.
"Physicians have faced years of undercompensation without ever abandoning Medicare patients," said Thomas Reardon, president of the AMA. "HCFA's ongoing refusal to use actual values in calculating the sustained growth rate is the equivalent of asking physicians to care for approximately one million Medicare patients annually without compensation."
Through 1999, the AMA worked with Congress to reach a bipartisan agreement that would eliminate problems with the sustained growth rate system in the future. The AMA said it supported the inclusion of improvements that were included in 1999's Balanced Budget Refinement Act, but said that steps must be taken to alleviate the burden resulting from HFCA's refusal to correct projection errors.
HCFA and HHS could not be reached for comment. PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.